Aminex Therapeutics: Funding, Investors & Team (Sep 2026)
Aminex Therapeutics, Inc. is a drug development company focused on the discovery, development, and commercialization of suppressor cell modulators (SCM), a new class of small molecule cancer immunotherapies that enable the immune system to attack cancer by regulating myeloid-derived suppressor cells. Aminex has extensively demonstrated, in animal trials, the potential of its lead drug, AMX-513, to be effective alone and to improve overall therapy when used in combination with other cancer treatments. Aminex's vision is to make significant treatment contributions for a wide range of cancers and to ease the rising costs of cancer therapy.
Aminex Therapeutics has raised $15.1M across 1 funding round on record, the most recent an undisclosed round of $15.1M announced in Dec 2025.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Aminex Therapeutics Company Profile and Key Stats
Latest funding round on record: Dec 2025.
Aminex Therapeutics Funding Rounds
Aminex Therapeutics Founders and Leadership Team
Contact details for the Aminex Therapeutics team: 1 of 1 has an email address on file.
Start 14-day free trial →Aminex Therapeutics Funding Compared to Other Biotechnology Startups
Aminex Therapeutics' latest round of $15.1M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Aminex Therapeutics in Biotechnology and Kirkland
Companies Similar to Aminex Therapeutics
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
Aminex Therapeutics Funding FAQs
What does Aminex Therapeutics do?
Aminex Therapeutics, Inc. is a drug development company focused on the discovery, development, and commercialization of suppressor cell modulators (SCM), a new class of small molecule cancer immunotherapies that enable the immune system to attack cancer by regulating myeloid-derived suppressor cells. Aminex has extensively demonstrated, in animal trials, the potential of its lead drug, AMX-513, to be effective alone and to improve overall therapy when used in combination with other cancer treatments. Aminex's vision is to make significant treatment contributions for a wide range of cancers and to ease the rising costs of cancer therapy.
How much funding has Aminex Therapeutics raised?
Aminex Therapeutics has raised $15.1M across 1 round on record. The most recent is an undisclosed round of $15.1M announced in Dec 2025.
When did Aminex Therapeutics last raise funding?
Aminex Therapeutics' most recent funding round on record is an undisclosed round of $15.1M, announced in Dec 2025.
Who founded Aminex Therapeutics?
FundedIQ lists Mark Burns (Founder) at Aminex Therapeutics.
Where is Aminex Therapeutics headquartered?
Aminex Therapeutics is based in Kirkland, Washington, United States.
How many employees does Aminex Therapeutics have?
Aminex Therapeutics is in the 1-10 employee band.
How does Aminex Therapeutics' funding compare to other Biotechnology startups?
Aminex Therapeutics' latest round of $15.1M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Aminex Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Aminex Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.